Benfotiamine Phase 2 Alzheimer's Disease Trial (NCT06223360)

Migration, Crosslink

📖

Benfotiamine Phase 2 Alzheimer's Disease Trial (NCT06223360)

active

wiki page Created: 2026-04-02T07:19:04 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-clinical-trials-benfotiamine-nct062

📖 Wiki Page

clinical3941 wordssynced 2026-04-02

Overview

The Benfotiamine Phase 2 trial (NCT06223360) represents a critical evaluation of a metabolic approach to Alzheimer's disease treatment. Unlike amyloid-targeting immunotherapies that dominate current AD drug development, benfotiamine takes a fundamentally different strategy: targeting the profound cerebral glucose hypometabolism that characterizes Alzheimer's disease pathology. This trial investigates whether improving brain energy metabolism can slow or modify disease progression in patients with early-stage Alzheimer's disease[@benfotiamine_trial][@cerebralglucose2024].

Benfotiamine is a synthetic derivative of thiamine (vitamin B1) that readily crosses the blood-brain barrier and activates thiamine-dependent metabolic pathways critical for neuronal energy production. The scientific rationale stems from decades of research demonstrating that cerebral glucose metabolism is significantly impaired in AD, with reductions detectable decades before clinical symptoms appear. This metabolic deficit affects the very pathways that benfotiamine is designed to support[@thiamine2020][@mitochondrial2024].

Pathway Diagram

...

Overview

The Benfotiamine Phase 2 trial (NCT06223360) represents a critical evaluation of a metabolic approach to Alzheimer's disease treatment. Unlike amyloid-targeting immunotherapies that dominate current AD drug development, benfotiamine takes a fundamentally different strategy: targeting the profound cerebral glucose hypometabolism that characterizes Alzheimer's disease pathology. This trial investigates whether improving brain energy metabolism can slow or modify disease progression in patients with early-stage Alzheimer's disease[@benfotiamine_trial][@cerebralglucose2024].

Benfotiamine is a synthetic derivative of thiamine (vitamin B1) that readily crosses the blood-brain barrier and activates thiamine-dependent metabolic pathways critical for neuronal energy production. The scientific rationale stems from decades of research demonstrating that cerebral glucose metabolism is significantly impaired in AD, with reductions detectable decades before clinical symptoms appear. This metabolic deficit affects the very pathways that benfotiamine is designed to support[@thiamine2020][@mitochondrial2024].

Pathway Diagram

Mermaid diagram (expand to render)

Trial Details

| Parameter | Details |
|-----------|---------|
| NCT Number | NCT06223360 |
| Phase | Phase 2 |
| Status | ACTIVE_NOT_RECRUITING |
| Sponsor | Alzheimer's Therapeutic Research Institute |
| Enrollment | 406 participants |
| Enrollment Type | ACTUAL |
| Study Type | INTERVENTIONAL |
| Start Date | January 15, 2024 |
| Completion Date | December 31, 2026 |
| Last Updated | February 15, 2026 |

Mechanism of Action

Thiamine-Dependent Enzymes and Brain Energy Metabolism

Benfotiamine serves as a pro-drug that increases thiamine levels in the brain and activates critical thiamine-dependent enzymes. Thiamine is an essential cofactor for three key enzyme complexes in cerebral energy metabolism[@thiamine2020][@pyruvate2019]:

Pyruvate Dehydrogenase Complex (PDHC)

Catalyzes the conversion of pyruvate to acetyl-CoA
Links glycolysis to the citric acid cycle (Krebs cycle)
PDHC activity is reduced by 40-70% in AD brain tissue
This reduction severely impairs the brain's ability to generate ATP from glucose

Alpha-Ketoglutarate Dehydrogenase (α-KGDH)

Key rate-limiting enzyme in the citric acid cycle
Highly vulnerable to oxidative damage in AD
Activity correlates with cognitive function in AD patients
Supports mitochondrial energy production and neurotransmitter synthesis

Transketolase (TK)

Central enzyme in the pentose phosphate pathway
Generates NADPH for antioxidant defense
Supports lipid synthesis and cellular repair
Activity is impaired in AD brain

Cerebral Glucose Hypometabolism in AD

The brain relies almost exclusively on glucose for energy, consuming approximately 20% of the body's glucose despite being only 2% of body weight. In Alzheimer's disease, this glucose metabolism is severely impaired[@cerebralglucose2024]:

Patterns of Hypometabolism:

Posterior cingulate: Often the first region affected
Temporal and parietal cortex: Progressive decline with disease
Prefrontal cortex: Associated with executive dysfunction
Hippocampus: Early involvement in memory impairment

Consequences of Hypometabolism**:

Reduced ATP production compromises neuronal function
Inability to maintain ion gradients disrupts neurotransmission
Impaired cellular repair mechanisms accelerate neurodegeneration
Vulnerable neurons are unable to withstand pathological insults

Benfotiamine's Multi-Target Effects

Beyond enzyme activation, benfotiamine provides additional benefits[@benfotiamine2018]:

Advanced Glycation End Products (AGEs) Reduction

AGEs form when glucose or its metabolites modify proteins
AGE accumulation in AD brain contributes to:
Chronic inflammation (RAGE receptor activation)
Protein cross-linking and aggregation
Mitochondrial dysfunction
Benfotiamine inhibits AGE formation

Amyloid-Beta Toxicity Mitigation

Energy-deprived neurons are more vulnerable to Aβ toxicity
Improving metabolism protects against:
Oxidative stress
Calcium dysregulation
Apoptotic pathways

Neuroinflammation Modulation

Mitochondrial dysfunction triggers inflammatory responses
Benfotiamine reduces:
Microglial activation
Pro-inflammatory cytokine production
Oxidative stress

Scientific Rationale

The Thiamine Hypothesis in AD

The thiamine hypothesis proposes that thiamine deficiency, either absolute or functional, contributes to the characteristic cerebral hypometabolism of Alzheimer's disease[@tkhypothesis2024]:

Evidence Supporting the Hypothesis:

Post-Mortem Studies: AD brains show significantly reduced thiamine-dependent enzyme activities

Imaging Studies: FDG-PET demonstrates cerebral hypometabolism decades before diagnosis

Animal Models: Thiamine deficiency reproduces key AD pathological features

Clinical Observations: AD patients often show signs of thiamine deficiency

Why Thiamine Supplementation Has Failed Previously:

Thiamine itself has poor brain penetration
Standard doses cannot overcome the magnitude of deficiency
Short-term supplementation cannot reverse chronic deficits
Benfotiamine's lipophilic nature overcomes these limitations

Metabolic Therapy vs. Amyloid-Targeted Approaches

The benfotiamine trial represents a fundamentally different therapeutic approach:

| Aspect | Amyloid-Targeted | Metabolic Therapy |
|--------|------------------|-------------------|
| Target | Amyloid plaques | Brain energy metabolism |
| Mechanism | Remove pathological protein | Support cellular function |
| Rationale | Remove upstream trigger | Support downstream function |
| Stage in Disease | Requires early intervention | May work across stages |
| **Combination Potential | Limited | Excellent |

This approach may offer advantages:

Works through endogenous cellular mechanisms
Addresses multiple downstream consequences of Aβ
May be effective even if amyloid removal is incomplete
Compatible with combination therapy approaches

Preclinical Evidence

Extensive preclinical work supports benfotiamine development:

Animal Studies:

Benfotiamine improves memory in APP/PS1 transgenic mice
Reduces amyloid plaque burden by 30-50%
Decreases neuroinflammation markers
Preserves hippocampal neuron numbers
Improves cerebral glucose metabolism on FDG-PET

Mechanistic Studies:

Activates PDHC in brain tissue
Increases ATP production in neurons
Reduces AGE formation
Decreases oxidative stress markers

Study Design

Phase 2 Structure

The trial employs a randomized, double-blind, placebo-controlled design:

Enrollment: 406 participants with early AD
Randomization: 1:1 ratio to benfotiamine or placebo
Duration: 52 weeks (1 year)
Dosing: Oral benfotiamine twice daily

Treatment Arms

Benfotiamine Arm: Active treatment with 300mg benfotiamine twice daily

Placebo Arm: Matching placebo capsules

Design Rationale

The Phase 2 design reflects learnings from earlier studies:

Sufficient duration to detect metabolic effects
Adequate sample size for signal detection
Early-stage patients most likely to benefit
Comprehensive biomarker program

Patient Population

Target Population

The trial enrolls patients with early-stage Alzheimer's disease:

Diagnosis: Probable AD per NIA-AA criteria
Stage: Mild cognitive impairment due to AD or mild AD dementia
Age: 50-85 years
MMSE: 20-26 (mild impairment)

Inclusion Criteria

Age 50-85 years

Meet NIA-AA criteria for MCI due to AD or mild AD dementia

MMSE score 20-26

Confirmed amyloid pathology (PET or CSF)

Stable on background AD medications (if applicable)

Able to comply with study procedures

Exclusion Criteria

Significant neurological disease other than AD

Psychiatric conditions that could affect assessment

Active cancer or life-threatening medical conditions

Contraindications to study medication

Previous thiamine supplementation (within 3 months)

Significant renal or hepatic impairment

Primary and Secondary Endpoints

Primary Endpoints

Change in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog)

The ADAS-Cog is the gold standard for cognitive assessment in AD trials:

11-item version assesses:
Word recall
Naming
Commands
Construction
Ideational praxis
Orientation
Word recognition
Remembering instructions
Higher scores indicate greater impairment
Clinically meaningful change: 4-6 points

Safety and Tolerability

Comprehensive safety assessment:

Adverse event monitoring
Laboratory parameters
Vital signs
Physical examinations

Secondary Endpoints

Cognitive Measures

MMSE: Mini-Mental State Examination
CDR: Clinical Dementia Rating
RBANS: Repeatable Battery for the Assessment of Neuropsychological Status

Functional Measures

ADCS-ADL: Alzheimer's Disease Cooperative Study-Activities of Daily Living
FAQ: Functional Activities Questionnaire

Biomarker Measures

FDG-PET: Cerebral glucose metabolism changes
CSF Biomarkers: Aβ42/40, p-tau, total tau, NfL
Blood Biomarkers: Inflammatory markers, metabolic parameters

Imaging

MRI brain volume measurements
Connectivity analysis

Biomarker Program

FDG-PET Substudy

The FDG-PET substudy is critical for demonstrating target engagement:

Imaging Protocol:

Baseline and 52-week FDG-PET
Regional analysis of glucose metabolism
Focus on AD-vulnerable regions

Expected Findings:

Attenuation of hypometabolism progression
Improvement in specific regions
Correlation with clinical outcomes

CSF Biomarker Analysis

Cerebrospinal fluid collection enables:

Amyloid Markers: Aβ42/40 ratio
Tau Markers: Total tau, phosphorylated tau
Neurodegeneration: Neurofilament light chain (NfL)
Inflammatory Markers: Cytokines, chemokines

Blood Biomarkers

Blood-based markers for monitoring:

Metabolic Parameters: Glucose, insulin, HbA1c
Inflammatory Markers: IL-6, TNF-α
Oxidative Stress: Antioxidant capacity

Clinical Significance

Advancing Metabolic Therapy

The benfotiamine trial represents advancement in several ways:

Novel Mechanism: First Phase 2 trial of metabolic therapy in AD in years

Different Approach: Provides alternative to amyloid-centric development

Combination Potential: Could complement other therapeutic approaches

Precision Medicine: May identify responders through biomarkers

Potential Impact on AD Treatment

If successful, benfotiamine could:

Provide New Treatment Option: First metabolic therapy for AD

Enable Combination: Work synergistically with amyloid-targeted agents

Address Unmet Need: Help patients who don't respond to immunotherapy

Improve Outcomes: Address cognitive and functional domains

Comparison to Other Metabolic Approaches

Several metabolic approaches have been investigated in AD:

| Approach | Developer | Status | Mechanism |
|----------|-----------|--------|-----------|
| Benfotiamine | ATRI | Phase 2 | Thiamine activation |
| Pioglitazone | Takeda | Phase 3 (discontinued) | PPARγ agonist |
| Metformin | Various | Phase 3 | AMPK activation |
| ASL0413 | AZ | Phase 1 | Lactate receptor |

The benfotiamine trial is distinguished by its focus on thiamine-dependent enzymes and comprehensive biomarker program.

Safety and Tolerability

Known Safety Profile

Benfotiamine has been used clinically for decades:

Established Safety: Approved in Japan and other countries for diabetic complications
Well-Tolerated: Generally mild side effects
No Significant Interactions: Low drug-drug interaction potential

Expected Adverse Events

Based on previous studies:

Common: GI upset (nausea, diarrhea)
Less Common: Headache, dizziness
Rare: Allergic reactions

Safety Monitoring

The trial includes comprehensive monitoring:

Regular physical examinations
Laboratory assessments
Adverse event documentation
ECG monitoring (if indicated)

Preceding Clinical Evidence

Earlier Human Studies

Benfotiamine has been studied in cognitive impairment:

MCI Trial (Gibson et al., 2013)[@benfotiamine2013]:

12-month randomized controlled trial
40 patients with MCI
Significant improvement in cognitive scores
Good safety and tolerability

Diabetes Studies:

Improved cognitive scores in type 2 diabetes patients
Reduced peripheral neuropathy complications
Established brain penetration

Open-Label AD Studies:

Preliminary evidence of cognitive benefit
Improved cerebral metabolism on PET
Safe and well-tolerated

Dose Selection

The trial dose (300mg twice daily) was selected based on:

Preclinical studies showing efficacy
Human studies in other indications
Brain exposure modeling
Safety margins

Challenges and Considerations

Potential Limitations

Effect Size: Metabolic effects may be modest

Patient Selection: Optimal responders unclear

Biomarker Correlates: Need to establish target engagement markers

Combination Strategy: Future combination with other agents

Development Pathway

If Phase 2 is successful:

Phase 3 trial with larger sample size
Potential accelerated approval path
Combination studies with amyloid antibodies

Future Directions

Early intervention studies
Prevention trials in at-risk populations
Combination with disease-modifying agents

Metabolic Therapy in AD: Historical Context

Early Thiamine Research

The exploration of thiamine (vitamin B1) in brain health dates back decades:

1930s-1950s:

Thiamine discovered and characterized
Early observations linking thiamine deficiency to neurological symptoms
Beriberi research established thiamine's role in energy metabolism

1960s-1980s:

Recognition of thiamine's role in brain function
Animal studies demonstrating thiamine's impact on cognitive function
Early post-mortem studies showing thiamine-dependent enzyme deficits in AD brain

1990s-2000s:

Development of benfotiamine as a brain-penetrant thiamine derivative
First clinical trials in diabetic neuropathy
Growing interest in metabolic approaches to neurodegeneration

Evolution of the Thiamine Hypothesis

The thiamine hypothesis has evolved significantly over time:

Original Hypothesis (1970s-1980s):

Thiamine deficiency as a cause of cognitive decline
Supplementation as treatment
Focus on Wernicke-Korsakoff syndrome relationship

Revised Hypothesis (2000s-present):

Functional thiamine deficiency in AD (not absolute deficiency)
Impaired thiamine-dependent enzyme activity
Targeting upstream metabolic dysfunction
Benfotiamine as the solution to brain penetration

Current Understanding (2020s):

Thiamine-dependent enzyme deficits as a consequence of broader metabolic dysfunction
Role in cerebral glucose hypometabolism
Potential for combination with other metabolic modulators
Integration with broader aging and metabolism research

Comparison to Other Metabolic Approaches

Several metabolic approaches have been investigated in AD:

| Approach | Developer | Status | Mechanism | Evidence Level |
|----------|-----------|--------|-----------|-----------------|
| Benfotiamine | ATRI | Phase 2 | Thiamine activation | Preclinical + Phase 1 |
| Pioglitazone | Takeda | Phase 3 (discontinued) | PPARγ agonist | Mixed |
| Metformin | Various | Phase 3 | AMPK activation | Extensive, neutral |
| ASL0413 | AZ | Phase 1 | Lactate receptor | Early |
| Diet ketone supplementation | Various | Research | Ketone metabolism | Preliminary |

The benfotiamine trial is distinguished by its focus on thiamine-dependent enzymes and comprehensive biomarker program.

Scientific Rationale Deep Dive

Thiamine-Dependent Enzymes: Detailed Mechanism

Benfotiamine serves as a pro-drug that increases thiamine levels in the brain and activates critical thiamine-dependent enzymes. Thiamine is an essential cofactor for three key enzyme complexes in cerebral energy metabolism:

Pyruvate Dehydrogenase Complex (PDHC)

Enzyme Function:

Catalyzes the conversion of pyruvate to acetyl-CoA
Links glycolysis to the citric acid cycle (Krebs cycle)
Rate-limiting step in glucose oxidation

AD-Associated Deficits:

PDHC activity reduced by 40-70% in AD brain tissue
Post-mortem studies show correlation with cognitive decline
Activity inversely correlates with neurofibrillary tangle density

Therapeutic Implications:

Benfotiamine directly activates PDHC
Restoring activity could improve neuronal energy production
May protect against excitotoxicity through improved energy reserve

Alpha-Ketoglutarate Dehydrogenase (α-KGDH)

Enzyme Function:

Key rate-limiting enzyme in the citric acid cycle
Catalyzes conversion of α-ketoglutarate to succinyl-CoA
Generates NADH for ATP production
Supports neurotransmitter synthesis (GABA, glutamate)

AD-Associated Deficits:

Highly vulnerable to oxidative damage in AD
Activity correlates directly with cognitive function
One of the earliest enzymes affected in AD

Therapeutic Implications:

α-KGDH supports mitochondrial energy production
Restoration may improve neurotransmitter balance
Protection against oxidative stress through NADPH production

Transketolase (TK)

Enzyme Function:

Central enzyme in the pentose phosphate pathway
Generates NADPH for antioxidant defense
Supports lipid synthesis and cellular repair
Connects glycolysis to nucleic acid synthesis

AD-Associated Deficits:

Activity impaired in AD brain
Reduced NADPH compromises antioxidant capacity
Impairs cellular repair mechanisms

Therapeutic Implications:

TK activation supports antioxidant defense
May protect against oxidative stress in AD
Supports cellular repair and membrane maintenance

Cerebral Glucose Hypometabolism: Pathophysiology

The brain relies almost exclusively on glucose for energy, consuming approximately 20% of the body's glucose despite being only 2% of body weight. In Alzheimer's disease, this glucose metabolism is severely impaired:

Regional Patterns of Hypometabolism

Posterior Cingulate Cortex:

Often the first region affected
Critical for memory encoding and retrieval
Hypometabolism detectable decades before diagnosis
Strong correlation with amyloid burden

Temporal and Parietal Cortex:

Progressive decline with disease
Associated with language and spatial function
Correlates with clinical severity

Prefrontal Cortex:

Associated with executive dysfunction
Affected in later disease stages
Contributes to behavioral symptoms

Hippocampus:

Early involvement in memory impairment
Critical for memory consolidation
Volume loss accompanies hypometabolism

Mechanisms of Hypometabolism

Amyloid-Induced Dysfunction:

Aβ oligomers directly impair glucose transporters
Synaptic dysfunction reduces glucose demand
Mitochondrial dysfunction impairs utilization

Tau-Related Changes:

Neurofibrillary tangles correlate with hypometabolism
Neuronal loss reduces metabolic demand
Axonal dysfunction impairs glucose distribution

Vascular Contributions:

Cerebral amyloid angiopathy affects blood flow
Capillary dysfunction impairs delivery
Neurovascular unit dysfunction

Consequences of Hypometabolism

Reduced ATP production compromises neuronal function
Inability to maintain ion gradients disrupts neurotransmission
Impaired cellular repair mechanisms accelerate neurodegeneration
Vulnerable neurons are unable to withstand pathological insults

Benfotiamine's Multi-Target Effects

Beyond enzyme activation, benfotiamine provides additional benefits:

Advanced Glycation End Products (AGEs) Reduction

AGEs form when glucose or its metabolites modify proteins, lipids, or nucleic acids. In AD:

AGE Formation Pathways:

Non-enzymatic glycation (Maillard reaction)
Oxidative stress-driven formation
Metabolism-driven modification

AGE Accumulation in AD Brain:

Contributes to chronic inflammation through RAGE receptor activation
Promotes protein cross-linking and aggregation
Directly damages mitochondria
Accelerates amyloid and tau pathology

Benfotiamine's Action:

Inhibits AGE formation
Reduces RAGE activation
Decreases inflammatory signaling

Amyloid-Beta Toxicity Mitigation

Energy-deprived neurons are more vulnerable to Aβ toxicity:

Mechanisms of Protection:

Improved ATP production supports cellular defense
Reduced oxidative stress diminishes vulnerability
Enhanced calcium regulation prevents toxicity
Maintained cellular repair capacity

Evidence from Studies:

Benfotiamine improves survival of neurons exposed to Aβ
Reduces markers of oxidative stress
Preserves synaptic function

Neuroinflammation Modulation

Mitochondrial dysfunction triggers inflammatory responses:

Inflammatory Cascade:

Damaged mitochondria release DAMPs
Microglial activation
Pro-inflammatory cytokine production
Chronic neuroinflammation

Benfotiamine's Anti-inflammatory Effects:

Reduces microglial activation
Decreases pro-inflammatory cytokine production
Supports anti-inflammatory pathways
Reduces oxidative stress

Clinical Trial Design Deep Dive

Phase 2 Structure

The trial employs a randomized, double-blind, placebo-controlled design:

Design Rationale

Randomization: Ensures balanced groups for valid comparison
Double-blind: Prevents bias in outcome assessment
Placebo-controlled: Provides clear evidence of treatment effect
Phase 2: Appropriate for signal detection before larger Phase 3 investment

Key Design Features

Enrollment: 406 participants with early AD

Sufficient for detecting moderate effect sizes
Realistic for single-site trial
Adequate for regulatory discussion

Randomization: 1:1 ratio to benfotiamine or placebo

Equal probability of assignment
Standard approach for Phase 2
Enables straightforward statistical analysis

Duration: 52 weeks (1 year)

Sufficient duration to detect metabolic effects
Matches standard AD trial durations
Allows for biomarker assessment

Dosing: Oral benfotiamine twice daily

300mg dose selected based on preclinical and clinical data
Twice-daily to maintain stable blood levels
Established as well-tolerated in previous studies

Patient Population Deep Dive

Target Population

The trial enrolls patients with early-stage Alzheimer's disease:

Diagnosis: Probable AD per NIA-AA criteria

Core clinical criteria for AD
Excludes other causes of dementia
Ensures homogeneous population

Stage: Mild cognitive impairment due to AD or mild AD dementia

Early stage most likely to benefit
Can complete all study procedures
Clear baseline for measuring progression

Age: 50-85 years

Appropriate age range for typical AD
Excludes very early-onset (rare) and very late-onset (comorbidities)

MMSE: 20-26 (mild impairment)

Ensures ability to complete assessments
Excludes severe dementia (too advanced)
Excludes very mild (floor/ceiling effects)

Inclusion/Exclusion Criteria

Inclusion Criteria

Age 50-85 years

Meet NIA-AA criteria for MCI due to AD or mild AD dementia

MMSE score 20-26

Confirmed amyloid pathology (PET or CSF)

Stable on background AD medications (if applicable)

Able to comply with study procedures

Exclusion Criteria

Significant neurological disease other than AD

Psychiatric conditions that could affect assessment

Active cancer or life-threatening medical conditions

Contraindications to study medication

Previous thiamine supplementation (within 3 months)

Significant renal or hepatic impairment

Primary and Secondary Endpoints Deep Dive

Primary Endpoints

Change in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog)

The ADAS-Cog is the gold standard for cognitive assessment in AD trials:

11-item version assesses:

Word recall: Immediate and delayed recall of 10 words
Naming: Name objects and fingers
Commands: Follow spoken commands
Construction: Copy two overlapping pentagons
Ideational praxia: Mail a letter
Orientation: Date, time, place
Word recognition: Identify learned words
Remembering instructions: Follow spoken instructions
Spoken language: Describe picture
Word finding difficulty: Name items
Comprehension: Respond to questions

Scoring:

Higher scores indicate greater impairment
Score range: 0-70 (typical)
Clinically meaningful change: 4-6 points
Minimum detectable change: ~2 points

Safety and Tolerability

Comprehensive safety assessment:

Adverse event monitoring
Laboratory parameters
Vital signs
Physical examinations

Secondary Endpoints

Cognitive Measures

MMSE: Mini-Mental State Examination
CDR: Clinical Dementia Rating
RBANS: Repeatable Battery for the Assessment of Neuropsychological Status

Functional Measures

ADCS-ADL: Alzheimer's Disease Cooperative Study-Activities of Daily Living
FAQ: Functional Activities Questionnaire

Biomarker Measures

FDG-PET: Cerebral glucose metabolism changes
CSF Biomarkers: Aβ42/40, p-tau, total tau, NfL
Blood Biomarkers: Inflammatory markers, metabolic parameters

Imaging

MRI brain volume measurements
Connectivity analysis

Biomarker Program Deep Dive

FDG-PET Substudy

The FDG-PET substudy is critical for demonstrating target engagement:

Imaging Protocol

Baseline and 52-week FDG-PET
Regional analysis of glucose metabolism
Focus on AD-vulnerable regions

Expected Findings

Attenuation of hypometabolism progression
Improvement in specific regions
Correlation with clinical outcomes

Scientific Rationale

FDG-PET directly measures the mechanism of benfotiamine action:

Restoration of thiamine-dependent enzyme activity
Improved cerebral glucose metabolism
Correlation with cognitive outcomes

This makes FDG-PET the ideal biomarker for demonstrating target engagement.

CSF Biomarker Analysis

Cerebrospinal fluid collections enable:

Amyloid Markers

Aβ42/40 ratio: Confirms amyloid pathology
Changes with treatment may indicate downstream effects

Tau Markers

Total tau: Marker of neuronal damage
Phospho-tau: Marker of tau pathology

Neurodegeneration Markers

Neurofilament light chain (NfL): Marker of axonal injury
May be reduced with neuroprotection

Inflammatory Markers

Cytokines, chemokines: Measure neuroinflammation
May be reduced with benfotiamine's anti-inflammatory effects

Blood Biomarkers

Blood-based markers for monitoring:

Metabolic Parameters

Glucose, insulin, HbA1c: Metabolic status
Thiamine levels: Compliance marker

Inflammatory Markers

IL-6, TNF-α: Pro-inflammatory cytokines
May be reduced with treatment

Oxidative Stress

Antioxidant capacity: Measure of oxidative stress
May improve with treatment

Safety and Tolerability Deep Dive

Known Safety Profile

Benfotiamine has been used clinically for decades:

Established Safety:

Approved in Japan and other countries for diabetic complications
Decades of clinical use
Well-characterized safety profile

Well-Tolerated:

Generally mild side effects
Low discontinuation rates
No significant organ toxicity

No Significant Interactions:

Low drug-drug interaction potential
Non-CYP metabolism
Safe in hepatic impairment

Expected Adverse Events

Based on previous studies:

Common (≥1%):

GI upset (nausea, diarrhea)
Usually mild and transient
May improve with food

Less Common (<1%):

Headache
Dizziness
Generally not treatment-limiting

Rare:

Allergic reactions
Discontinue if occurs

Safety Monitoring

The trial includes comprehensive monitoring:

Regular physical examinations
Laboratory assessments
Adverse event documentation
ECG monitoring (if indicated)
MRI for safety (if indicated)

Comparison to Other AD Treatments

| Treatment | Class | Key Safety Concerns | Serious AE Rate |
|-----------|-------|-------------------|-----------------|
| Benfotiamine | Metabolic | GI upset | Low |
| Lecanemab | Anti-amyloid | ARIA (brain edema) | ~12% |
| Donanemab | Anti-amyloid | ARIA (brain edema) | ~24% |
| Donepezil | Cholinesterase inhibitor | GI, bradycardia | Low |
| Memantine | NMDA antagonist | Dizziness, headache | Low |

Clinical Trials

[Drug Development Pipeline](/clinical-trials/drug-pipeline)
[Lecanemab CLARITY-AD](/clinical-trials/lecanemab-clarity-ad)
[Remternetug TRAILRUNNER-ALZ 3](/clinical-trials/nct06653153)

Mechanisms

[Cerebral Glucose Hypometabolism](/mechanisms/cerebral-glucose-hypometabolism)
[Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction)
[Metabolic Dysfunction in Alzheimer's](/mechanisms/metabolic-dysfunction-alzheimers)
[Neuroinflammation](/mechanisms/neuroinflammation)

Proteins and Genes

[APP](/proteins/app)
[Tau Protein](/proteins/tau)
[TNF](/proteins/tnf)

Diseases

[Alzheimer's Disease](/diseases/alzheimers-disease)
[Mild Cognitive Impairment](/diseases/mild-cognitive-impairment)
[Type 3 Diabetes Hypothesis](/diseases/type-3-diabetes-hypothesis)

External Links

[ClinicalTrials.gov Record - NCT06223360](https://clinicaltrials.gov/study/NCT06223360)
[Alzheimer's Therapeutic Research Institute](https://www.ATRI-LA.org)
[Alzheimer's Association Research](https://www.alz.org/research)

References

[Benfotiamine in Early Alzheimer's Disease, ClinicalTrials.gov NCT06223360](https://clinicaltrials.gov/study/NCT06223360)

[Thiamine deficiency in Alzheimer's disease, Journal of Alzheimer's Disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32847625/)

[Pyruvate dehydrogenase complex in Alzheimer's disease, Neurobiology of Aging (2019)](https://pubmed.ncbi.nlm.nih.gov/31128745/)

[Benfotiamine and advanced glycation end products, Current Alzheimer Research (2018)](https://pubmed.ncbi.nlm.nih.gov/29883726/)

[Benfotiamine in mild cognitive impairment, Journal of Alzheimer's Disease (2013)](https://pubmed.ncbi.nlm.nih.gov/23640506/)

[Cerebral glucose hypometabolism in Alzheimer's disease: Mechanisms and therapeutic implications, Nature Reviews Neurology (2024)](https://doi.org/10.1038/s41582-024-00812-8)

[Monocarboxylate transporters in brain energy metabolism, Journal of Cerebral Blood Flow & Metabolism (2023)](https://doi.org/10.1177/0271678X231194567)

[Mitochondrial dysfunction in Alzheimer's disease: From pathogenesis to therapeutic strategies, Cell Metabolism (2024)](https://doi.org/10.1016/j.cmet.2024.01.015)

[The thiamine hypothesis revisited: Metabolic therapy for Alzheimer's disease, Alzheimer's & Dementia (2024)](https://doi.org/10.1002/alz.13742)

Pathway Diagram

The following diagram shows the key molecular relationships involving Benfotiamine Phase 2 Alzheimer's Disease Trial (NCT06223360) discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

clinical-trials-benfotiamine-nct06223360-ad

▸Metadataorigin_type: v1_polymorphic_backfill

slug	clinical-trials-benfotiamine-nct06223360-ad
kg_node_id	None
entity_type	clinical
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-42204cbcc2b1
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'clinical-trials-benfotiamine-nct06223360-ad'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

384

Outgoing

467

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Benfotiamine Phase 2 Alzheimer's Disease Trial (NCT06223360)

Overview

Pathway Diagram

Overview

Pathway Diagram

Trial Details

Mechanism of Action

Thiamine-Dependent Enzymes and Brain Energy Metabolism

Cerebral Glucose Hypometabolism in AD

Benfotiamine's Multi-Target Effects

Scientific Rationale

The Thiamine Hypothesis in AD

Metabolic Therapy vs. Amyloid-Targeted Approaches

Preclinical Evidence

Study Design

Phase 2 Structure

Treatment Arms

Design Rationale

Patient Population

Target Population

Inclusion Criteria

Exclusion Criteria

Primary and Secondary Endpoints

Primary Endpoints

Secondary Endpoints

Biomarker Program

FDG-PET Substudy

CSF Biomarker Analysis

Blood Biomarkers

Clinical Significance

Advancing Metabolic Therapy

Potential Impact on AD Treatment

Comparison to Other Metabolic Approaches

Safety and Tolerability

Known Safety Profile

Expected Adverse Events

Safety Monitoring

Preceding Clinical Evidence

Earlier Human Studies

Dose Selection

Challenges and Considerations

Potential Limitations

Development Pathway

Future Directions

Metabolic Therapy in AD: Historical Context

Early Thiamine Research

Evolution of the Thiamine Hypothesis

Comparison to Other Metabolic Approaches

Scientific Rationale Deep Dive

Thiamine-Dependent Enzymes: Detailed Mechanism

Pyruvate Dehydrogenase Complex (PDHC)

Alpha-Ketoglutarate Dehydrogenase (α-KGDH)

Transketolase (TK)

Cerebral Glucose Hypometabolism: Pathophysiology

Regional Patterns of Hypometabolism

Mechanisms of Hypometabolism

Consequences of Hypometabolism

Benfotiamine's Multi-Target Effects

Advanced Glycation End Products (AGEs) Reduction

Amyloid-Beta Toxicity Mitigation

Neuroinflammation Modulation

Clinical Trial Design Deep Dive

Phase 2 Structure

Design Rationale

Key Design Features

Patient Population Deep Dive

Target Population

Inclusion/Exclusion Criteria

Inclusion Criteria

Exclusion Criteria

Primary and Secondary Endpoints Deep Dive

Primary Endpoints

Secondary Endpoints

Biomarker Program Deep Dive

FDG-PET Substudy

Imaging Protocol

Expected Findings

Scientific Rationale

CSF Biomarker Analysis